澱粉樣蛋白(Amyloid beta, Aβ)長期以來一直被認為是阿茲海默症的主要病理因子。研究發現，血漿中的Aβ42具有極高的錯誤結構形成趨勢並形成有毒的聚集體，因此與一個人患有或發展阿茲海默症的可能性高度相關，即使在沒有觀察到認知能力下降的情況下也是如此。因此，測量血液中Aβ的濃度成為一種有前景的非侵入性阿茲海默症早期檢測工具。相比基於常見認知測試的阿茲海默症診斷方法，這種檢測方法可以在病情進展到最終階段之前進行診斷。我們致力於開發一種基於磁性奈米粒子和量子點的診斷方法，以實現這一潛力。具體而言，我們使用Aβ42特異性抗體捕獲血漿中的澱粉樣蛋白，並利用磁性奈米粒子和量子點實現反向分析策略，簡化了確定Aβ42濃度的分析過程。這種多重、敏感和快速的診斷方法預計將成為阿茲海默症診斷和監測的有價值的工具。;The peptide family of amyloid beta (Aβ) has long been suspected to be a major pathogenic culprit for Alzheimer′s disease (AD). Research has found that Aβ42 in plasma exhibits a pronounced tendency to form erroneous structures and generate toxic aggregates. Consequently, there is a strong correlation between the presence of Aβ42 and the likelihood of developing or experiencing Alzheimer′s disease, even in individuals without apparent cognitive decline. Therefore, measuring the concentration of Aβ in blood has emerged as a promising non-invasive tool for early detection of Alzheimer′s disease. This detection method, compared to conventional cognitive tests-based diagnostic approaches, allows for diagnosis before the disease progresses to its final stages. We have been developing a diagnostic method based on magnetic nanoparticles and quantum dots to realize this potential. Specifically, we use Aβ42-specific antibodies to capture the peptide in plasma, and employ magnetic nanoparticles and quantum dots to implement a reverse assay strategy, simplifying the analysis process for determining the concentration of Aβ42. This multiplex, sensitive, and rapid diagnostic method is expected to become a valuable tool for Alzheimer′s disease diagnosis and monitoring.
